➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Mallinckrodt
Moodys
Express Scripts
McKesson

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

Allergan Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for Allergan

Drugs and US Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan RESTASIS cyclosporine EMULSION;OPHTHALMIC 050790-001 Dec 23, 2002 RX Yes Yes 8,642,556 ⤷  Try it Free Y ⤷  Try it Free
Allergan OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 OTC Yes Yes ⤷  Try it Free ⤷  Try it Free
Allergan NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-004 Jul 18, 2016 RX Yes No 8,362,085*PED ⤷  Try it Free Y ⤷  Try it Free
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes 7,851,504 ⤷  Try it Free Y Y ⤷  Try it Free
Allergan ACTIGALL ursodiol CAPSULE;ORAL 019594-002 Dec 31, 1987 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes 9,241,918 ⤷  Try it Free Y ⤷  Try it Free
Allergan ACULAR PRESERVATIVE FREE ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 020811-001 Nov 3, 1997 DISCN No No ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 5,601,839 ⤷  Try it Free
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-002 Sep 29, 2000 5,089,509 ⤷  Try it Free
Allergan BYSTOLIC nebivolol hydrochloride TABLET;ORAL 021742-004 Dec 17, 2007 5,759,580 ⤷  Try it Free
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-001 Sep 29, 2000 5,089,509 ⤷  Try it Free
Allergan OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 7,179,483 ⤷  Try it Free
Allergan SAPHRIS asenapine maleate TABLET;SUBLINGUAL 022117-001 Aug 13, 2009 5,763,476*PED ⤷  Try it Free
Allergan OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 7,081,252 ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 400 mg/vial and 600 mg/vial ➤ Subscribe 2014-10-29
➤ Subscribe Suppository 1000 mg ➤ Subscribe 2013-05-24
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-23
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2017-06-09
➤ Subscribe Ophthalmic Solution 0.10% ➤ Subscribe 2006-12-20
➤ Subscribe Tablets 10 mg, 20 mg, and 40 mg ➤ Subscribe 2015-01-21
➤ Subscribe Extended-release Capsules 20 mg, 40 mg, 80 mg and 120 mg ➤ Subscribe 2017-07-25
➤ Subscribe Ophthalmic Solution 0.2%/0.5% ➤ Subscribe 2008-11-21
➤ Subscribe Sublingual Tablets 2.5 mg ➤ Subscribe 2017-07-27
➤ Subscribe Capsules 21 mg/10 mg ➤ Subscribe 2016-09-23
➤ Subscribe Ophthalmic Solution 0.25% ➤ Subscribe 2014-07-30
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 2009-03-02
➤ Subscribe Ophthalmic Solution 0.01% ➤ Subscribe 2011-04-05
➤ Subscribe Capsules 140 mg/125 mg/ 125 mg ➤ Subscribe 2014-08-12
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2010-12-07
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe 2008-08-19
➤ Subscribe Capsules 5 mg ➤ Subscribe 2005-08-17
➤ Subscribe Gel 10% ➤ Subscribe 2014-06-19
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2007-10-16
➤ Subscribe Ophthalmic Solution 0.40% ➤ Subscribe 2005-01-28
➤ Subscribe Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg ➤ Subscribe 2011-12-19
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-24
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe 2013-01-14
➤ Subscribe Ophthalmic Solution 0.15% ➤ Subscribe 2006-11-03
➤ Subscribe Sublingual Tablets 5 mg and 10 mg ➤ Subscribe 2013-08-13
➤ Subscribe Capsules 14 mg/10 mg and 28 mg/10 mg ➤ Subscribe 2015-05-18
➤ Subscribe Ophthalmic Solution 0.05% ➤ Subscribe 2008-10-14
➤ Subscribe Capsules 7 mg/10 mg ➤ Subscribe 2016-09-26
➤ Subscribe Ophthalmic Solution 0.03% ➤ Subscribe 2008-12-22
➤ Subscribe Capsules 145 mcg and 290 mcg ➤ Subscribe 2016-08-30
➤ Subscribe Ophthalmic Solution 0.30% ➤ Subscribe 2007-07-19
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 2012-10-09
➤ Subscribe Topical Solution 0.03% ➤ Subscribe 2010-05-03
➤ Subscribe Gel 7.5% ➤ Subscribe 2017-02-13
➤ Subscribe Capsules 10 mg and 20 mg ➤ Subscribe 2005-03-30

Supplementary Protection Certificates for Allergan Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992 SPC/GB13/061 United Kingdom ⤷  Try it Free PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624
2176234 17C1005 France ⤷  Try it Free PRODUCT NAME: ELUXADOLINE; REGISTRATION NO/DATE: EU/1/16/1126 20160921
0770388 09C0018 France ⤷  Try it Free PRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103
1480644 122016000105 Germany ⤷  Try it Free PRODUCT NAME: CEFTAZIDIM ODER EIN SALZ DAVON MIT AVIBACTAM ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1109 20160624
1304992 C01304992/01 Switzerland ⤷  Try it Free PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
1725537 CA 2017 00008 Denmark ⤷  Try it Free PRODUCT NAME: ELUXADOLIN ELLER EN FARMACEUTISK ACCEPTABEL ENANTIOMER, DIASTEREOMER, RACEMAT ELLER SALT DERAF; REG. NO/DATE: EU/1/16/1126 20160921
1043327 CA 2013 00003 Denmark ⤷  Try it Free
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Harvard Business School
Express Scripts
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.